

Review Form 1.7

| | |
|--------------------------|--|
| Journal Name: | Ophthalmology Research: An International Journal |
| Manuscript Number: | Ms_OR_109056 |
| Title of the Manuscript: | Docetaxel-induced bilateral cystoid macular edema seems not cumulative dose dependent: A case report. |
| Type of the Article | Case study |

Review Form 1.7

PART 1: Review Comments

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|--|--|---|
| <p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p> | <p>Yes</p> <p>Yes (See the attachment)</p> <p>Not appropriate, See the attachment</p> <p>Not appropriate, needs modification</p> <p>Yes</p> <p>Yes, Additional references are here under</p> <ol style="list-style-type: none"> 1. Docetaxel induced maculopathy possibly potentiated by concurrent – www.ncbi.nlm.nih.in 2. Drug influenced maculopathy-www.eyewiki.ovao.org | |
| <p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p> | <p>Fair</p> | |
| <p>Optional/General comments</p> | <p>This article a case study titled “Docetaxel-induced bilateral cystoid macular edema seems not cumulative dose dependent: A case report” is devoid of many paragraphs that are needed to make it a comprehensive case study. Any article whether it is a case study, research work, exploratory or otherwise, one should follow certain norms which are necessitated make it a comprehensive study.</p> <p>Abstract:</p> <p>The Abstract should contain aim and objectives of the study or hypothesis in case of a case study and then sample and sampling methods, discussions and results, with suggestions and observations finally findings. So, to say a Abstract is the crux of the entire study and should represent all the ingredients of the article in a brief manner not exceeding 300 to 350 words.</p> <p>Comments: The author should rewrite the Abstract, the suggestions mentioned above,</p> <p><u>Aim, Objective or Hypothesis of the study:</u> Not mentioned</p> | |

Review Form 1.7

| | | |
|--|---|--|
| | <p>From the study, the Hypothesis can be drawn as,</p> <p><i>“In order to understand whether Docetaxel-induced bilateral cystoid macular edema is dependent on cumulative dose?”</i></p> <p>Sample and Sampling: Not mentioned separately</p> <p>Comments: This can be drawn from the Article that should be separated mentioned in the case report,</p> <p><i>“This case study is based on the case of a woman with no history of High Blood Pressure, Diabetes, Ocular or systemic inflammatory disease, followed for breast cancer.”</i> The patient has already received three cycles of chemotherapy, every three weeks based on Docetaxel 150 mg, perjeta 420 mg and trastuzumab 360 mg, three days after her second course of chemotherapy, she reported a decrease in her visual activity and was referred by her attending physician for an Ophthalmological opinion.</p> <p>Consent: Not obtained</p> <p>It is mandatory to obtain written consent from the patient because, the patient’s health records are used. Not obtaining written consent from the patient attracts legal provision.</p> <p>Suggestions/Recommendations: Not separately mentioned</p> <p>Comments: From the article, the suggestions and recommendations that are identified are mentioned below and have to be separately paragraphed.</p> <p><i>“a. This leaves us to suggest that taxanes toxicity can appear early and does not depend on cumulative dose. To our knowledge our patient is the first case reported in the literature with a time to onset of macular edema not exceeding one month (Page No. 3 para 2).</i></p> <p><i>b. Toxic cystoid macular edema (T-CME) is a rare complication caused by Docetaxel the exact mechanism is unclear and the best treatment is to stop this the causative agent “(Page no. 4 para 2) in conclusion part.</i></p> <p>Observation: Not mentioned separately</p> <p>From the article the observation part is mentioned below and that has to be paragraphed</p> | |
|--|---|--|

Review Form 1.7

| | | |
|--|--|--|
| | <p>separately.</p> <p>a. Fluorescein angiography showed normal filling of the choroidal and retinal vessels and an unremarkable parafoveal capillary network and no fluorescein leakage on the late angiograms phases (figure 2).</p> <p>A toxic maculopathy, related to either Herceptin or Docetaxel, was mentioned and her oncologist was notified.</p> <p>However, the treatment was not interrupted, with four more cycles before stopping Docetaxel, and then switching to chemotherapy cycles based only on Perjeta 420 and Herceptin 360mg every 3 weeks.</p> <p>One month after stopping Docetaxel, visual acuity began to improve to reach 20/20 in both eyes at the third month. Macular control SD-OCT shows total resorption of the macular edema without sequelae (figure 3). (Page No. 2 in Case Study)</p> <p>b. For our patient, the macular syndrome appeared three days after the second course of Docetaxel chemotherapy, which corresponds to 24 days after starting this medication with a cumulative dose of only 300mg (120 mg/m²). (Page No. 2 para 2)</p> <p>Results: Not mentioned separately</p> <p>Comments: The good clinical and tomographic improvement after discontinuation of Docetaxel, allowed us to retain the macular toxicity effect of this product in this patient. (Page No. 2 para 2)</p> <p>This suggests no cumulative dose is needed for macular edema to appear (Page NO. 4 last sentence)</p> <p>Future Study: Not mentioned</p> <p>Risk Factor: Not mentioned</p> <p>Ethical Issues: Any study a living human being is involved ethical consent from the respective committee should be obtained.</p> | |
|--|--|--|

Review Form 1.7

| | | |
|--|---|--|
| | <p>Limitations: Not study'</p> <p>Whether it is a research work or a case study. There are certain limitations beyond which the study cannot be provided. Hence, the author should mention what are the limitations of the study.</p> | |
|--|---|--|

PART 2:

| | Reviewer's comment | Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i> |
|---|--|---|
| Are there ethical issues in this manuscript? | <i>(If yes, Kindly please write down the ethical issues here in details)</i> | |

Reviewer Details:

| | |
|----------------------------------|------------------------------------|
| Name: | C. L. Avadhani |
| Department, University & Country | Annamalai University, India |